Skip to content
NewsBlazeAU – Lifestyle
Author:
argenx SE
argenx to Present at Upcoming Investor Conferences
November 3, 2026
argenx Reports Third Quarter 2026 Financial Results and Provides Business Update
October 22, 2026
argenx to Present Phase 3 ALKIVIA Results in Autoimmune Myositis as a Late-Breaking Oral Presentation at ACR Convergence 2026
October 19, 2026
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
October 15, 2026
argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren’s Disease
October 8, 2026
argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
October 8, 2026
argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
September 29, 2026
argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
September 17, 2026
argenx to Present at Upcoming Investor Conferences
September 1, 2026
argenx Announces Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis
August 17, 2026
1
2
3
Next Page
→